CTOs on the Move

Apnimed

www.apnimed.com

 
Apnimed is a clinical-stage company focused on advancing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.apnimed.com
  • 39 John F. Kennedy Street 4th Floor
    Cambridge, MA USA 02138
  • Phone: 617.500.8880

Executives

Name Title Contact Details

Funding

Apnimed raised $62.5M on 05/04/2022

Similar Companies

Global Animal Management

Global Animal Management is a Union, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Hydropothecary

The Hydropothecary is a licensed producer and distributor of medical marijuana under Health Canada`s Access to Cannabis for Medical Purposes Regulations (ACMPR). We are committed to medical excellence and achieve this through our growing techniques, process control, quality assurance testing, robust research and development, and by offering an exceptional customer service experience. We are proud of our company`s remarkable growth thus far and look forward to our continued expansion with the construction of a new greenhouse which will boast an additional 250,000 sq/ft in 2018. We are constantly seeking skilled, energetic and highly focused p-professionals who would like the opportunity to be a part of our team and of an exciting industry that is constantly evolving.

Avecia Biotechnology

Avecia Biotechnology is a Milford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Youth Home

Youth Home, Inc. is a non-profit psychiatric treatment center located in Little Rock, Arkansas for emotionally troubled adolescents and their families.

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).